Search / Trial NCT00002456

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

Launched by FRED HUTCHINSON CANCER CENTER · Apr 23, 2004

Trial Information

Current as of December 06, 2024

Completed

Keywords

Recurrent Childhood Acute Lymphoblastic Leukemia Childhood Non Hodgkin Lymphoma Recurrent Childhood Lymphoblastic Lymphoma Recurrent Childhood Acute Myeloid Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Adult Acute Lymphoblastic Leukemia Relapsing Chronic Myelogenous Leukemia Refractory Chronic Lymphocytic Leukemia Recurrent Adult Non Hodgkin Lymphoma Graft Versus Host Disease

ClinConnect Summary

OBJECTIVES: I. Determine the efficacy of a combination of methotrexate and cyclosporine, administered after grafting, to prevent the development of acute graft versus host disease (GVHD) in patients undergoing allogeneic bone marrow transplantation.

OUTLINE: Patients receive methotrexate IV on days 1,3,6, and 11. Patients also receive cyclosporine IV twice a day until the patient is eating, then it is administered orally twice a day. Cyclosporine begins on day -1 and continues until day 180. The dose is reduced beginning on day 50.

PROJECTED ACCRUAL: Accrual will continue until further no...

Gender

ALL

Eligibility criteria

  • DISEASE CHARACTERISTICS: Ongoing bone marrow transplantation from HLA-matched siblings or HLA non-identical family members or unrelated donor
  • PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy: Not severely limited by disease other than leukemia Hematopoietic: Not specified Hepatic: No severe hepatic disease Renal: No history of hemorrhagic cystitis No renal disease Cardiovascular No symptomatic cardiac disease Other: No contraindication to the use of cyclosporine or methotrexate
  • PRIOR CONCURRENT THERAPY: No concurrent experimental treatment on other GVHD prophylaxis studies

Trial Officials

Rainer F. Storb, MD

Study Chair

Fred Hutchinson Cancer Center

About Fred Hutchinson Cancer Center

Fred Hutchinson Cancer Center is a leading nonprofit research institution dedicated to the pursuit of innovative cancer treatments and prevention strategies. Established in Seattle, Washington, the center is renowned for its pioneering work in hematopoietic cell transplantation and its commitment to advancing cancer research through collaborative clinical trials. By integrating cutting-edge science with compassionate patient care, Fred Hutchinson Cancer Center aims to improve outcomes for patients while fostering a multidisciplinary approach to tackling complex cancer challenges. With a strong emphasis on translating research findings into clinical applications, the center is at the forefront of developing novel therapies that offer hope to patients worldwide.

Locations

Seattle, Washington, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials